Health news
The Food and Drug Administration (FDA) has granted accelerated approval to Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of individuals 6 years of age and older with unresectable or metastatic solid tumors with BRAF…
Patients with common cancers are generally more likely to die from causes other than their cancer, according to research published in JNCI Cancer Spectrum.1 The study suggested that, for most common cancers, patients who survived…
Adding oleclumab or monalizumab to consolidation with durvalumab can improve clinical outcomes in patients with unresectable stage III non-small cell lung cancer (NSCLC), a phase 2 trial suggests. Combining durvalumab with oleclumab or monalizumab produced…
A phase 3 trial evaluating tiragolumab in combination with atezolizumab (Tecentriq®) in adults with PD-L1 high locally advanced or metastatic non-small cell lung cancer (NSCLC) did not meet its coprimary endpoint of progression-free survival (PFS),…
Many reports of cancer drug trials frame quality of life (QOL) outcomes in an inaccurate or misleading way, according to research published in JAMA Oncology. Researchers found favorable reports of QOL outcomes for roughly half…
A new cancer diagnosis is independently associated with a higher risk of cardiovascular death, according to a large study published in JACC: CardioOncology. The study also showed an increased risk of stroke, heart failure, and…
The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Eli Lilly and Company regarding the Biologics License Application (BLA) for sintilimab in combination with pemetrexed and platinum chemotherapy for the…
The likelihood that a patient with cancer will receive guideline-concordant treatment varies according to cancer type, age, comorbidities, and center volume, according to a study published in Advances in Radiation Oncology. Researchers aimed to evaluate…
As many as 1 in 5 cancer patients enrolled in phase 3 clinical trials may use complementary medicine, according to a study published in The Oncologist. The study also showed superior outcomes among patients taking…
The Food and Drug Administration (FDA) has accepted the New Drug Application for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least 1…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021